GlaxoSmithKline plc
Pharmaceuticals & BiotechnologyFounded 1715- Updated June 2026
Reviewed by Swet Parvadiya
Last reviewed: June 2026
CorpDigest
GlaxoSmithKline plc
Company History
Founded 2024 in London, United Kingdom
Last reviewed: 2026-06-09 · By Swet Parvadiya
The company's pricing power in the US market, where 42 percent of total revenue originates, remains a critical component of its financial model, allowing it to implement average annual price increases of 4.5 percent on its specialty portfolio, offsetting the volume erosion caused by generic competition in the General Medicines division. The competitive intensity is further exacerbated by the entry of biosimilar manufacturers in the General Medicines division, where companies like Sandoz and Teva have launched generic versions of Advair and Ventolin, driving the average selling price of GSK's respiratory portfolio down by 68 percent since 2022 and forcing the company to rely entirely on the volume growth of Trelegy Ellipta to maintain revenue stability. The AS01 platform represents a century of cumulative immunological research, dating back to the original discovery of the adjuvant properties of mycobacterial cell walls in the 1930s, and the institutional knowledge required to optimize the lipid A extraction and QS-21 purification processes is held by a specialized team of 140 scientists at the GSK Vaccines institute in Wavre, Belgium, a talent concentration that cannot be replicated through simple hiring or acquisition. This original entity, which operated under the name Plough Court Pharmacy, primarily compounded herbal remedies and tinctures for the local population, but it was the subsequent acquisition of the pharmacy by Allen & Hanburys in 1873 that transformed it into a major pharmaceutical manufacturer, introducing the first commercial inhaler for asthma in 1892.
The Glaxo name originated in 1892 when Joseph Nathan, a New Zealand-based merchant, established a subsidiary to import and distribute powdered milk products under the brand name 'Glaxo,' derived from the Latin word for ice, reflecting the company's initial focus on nutrition rather than pharmaceuticals. The American lineage of the company began in 1830 when Silas M. Smith opened a herbal medicine shop in New York, which was subsequently joined by his nephew Mahlon Kline in 1871 to form Smith, Kline & French, a company that would become famous for the introduction of the first mass-produced amphetamine inhaler in 1930 and the blockbuster antidepressant Paxil in 1992.
Silvanus Bevan was an 18th-century apothecary who founded the Plough Court Pharmacy in London in 1715, the earliest ancestral entity of what would eventually become GlaxoSmithKline. Operating during a period when the pharmaceutical profession was largely unregulated and dominated by quackery, Bevan distinguished himself by adhering to strict compounding standards and sourcing the highest quality raw materials for his herbal remedies and tinctures. His pharmacy became a trusted resource for the local population and the emerging medical community, establishing a reputation for quality and integrity that would be carried forward by subsequent generations of owners. Bevan's decision to focus on scientific rigor rather than quick profits set the foundational culture for the enterprise, a culture that would survive the Industrial Revolution, the Great Plague, and the modern biotechnology revolution. The Plough Court Pharmacy was subsequently acquired by Allen & Hanburys in 1873, which transformed it into a major pharmaceutical manufacturer, but the core values established by Bevan in 1715 remained central to the company's identity. His legacy is not one of specific scientific discoveries, but of the institutional commitment to quality and ethical business practices that has allowed the entity to survive and thrive for over three centuries.
Joseph Nathan was a New Zealand-based merchant who established the Glaxo brand in 1892, creating the entity that would eventually merge with Wellcome to form Glaxo Laboratories. Initially, the company focused on importing and distributing powdered milk products, a decision driven by the high demand for infant nutrition in the colonial markets of the Pacific. Nathan's choice of the brand name 'Glaxo,' derived from the Latin word 'glacies' meaning ice, was a strategic branding decision that emphasized the purity and preservation qualities of the product, a marketing message that resonated strongly with consumers concerned about food safety. The Glaxo brand became highly successful in the Australasian market, allowing Nathan to expand the business into the United Kingdom in the early 20th century. The company's transition from nutrition to pharmaceuticals began in the 1930s when it acquired the dairy company Greensborough and subsequently began manufacturing vitamin D supplements, a natural extension of its expertise in nutritional science. This strategic pivot laid the groundwork for the company's eventual merger with Allen & Hanburys in 1958 and its subsequent evolution into a major pharmaceutical player. Nathan's legacy is the creation of a powerful brand identity that emphasized purity and scientific quality, a brand that would become synonymous with pharmaceutical excellence in the UK and beyond.
Silas M. Smith was an American entrepreneur who opened a herbal medicine shop in New York in 1830, establishing the earliest ancestral entity of what would become SmithKline Beecham. Operating during a period of rapid industrialization and westward expansion in the United States, Smith recognized the growing demand for standardized, mass-produced medicinal products. His decision to partner with his nephew Mahlon Kline in 1871 was a pivotal moment in the company's history, as Kline brought formal pharmaceutical training and a focus on scientific manufacturing processes that transformed the business from a simple retail operation into a major pharmaceutical manufacturer. The newly formed Smith, Kline & French quickly gained a reputation for quality and innovation, introducing the first mass-produced amphetamine inhaler in 1930 and the blockbuster antidepressant Paxil in 1992. The company's American lineage was characterized by a strong commercial focus and a willingness to invest in new technologies, a culture that would eventually clash with the more research-oriented culture of the British Glaxo Wellcome when the two companies merged in 2000. Smith's legacy is the creation of a commercially driven pharmaceutical enterprise that would become one of the largest and most successful drug manufacturers in the United States, setting the stage for the monumental 2000 merger that created the modern GlaxoSmithKline.
Silvanus Bevan opens a small pharmacy at Plough Court in London, establishing the earliest ancestral entity of GlaxoSmithKline, which would accumulate over three centuries of continuous operational history.
Joseph Nathan establishes the Glaxo brand in New Zealand, initially focusing on powdered milk products, a decision that would later provide the foundation for the company's transition into pharmaceutical manufacturing.
Silas M. Smith's herbal medicine shop is joined by his nephew Mahlon Kline to form Smith, Kline & French, introducing the first mass-produced amphetamine inhaler and establishing a major American pharmaceutical manufacturer.
Glaxo Laboratories acquires the pharmaceutical company Allen & Hanburys, which had previously acquired the Plough Court Pharmacy, creating a major British pharmaceutical entity with a strong respiratory franchise.
Glaxo Laboratories merges with the Wellcome Foundation to form Glaxo Wellcome, creating a $15 billion pharmaceutical powerhouse with a dominant position in the anti-ulcer and antiviral markets.
Glaxo Wellcome and SmithKline Beecham merge in a $76 billion transaction, creating the world's largest pharmaceutical company by market capitalization with $24 billion in annual revenue and 100,000 employees.
GSK forms a consumer healthcare joint venture with Novartis, acquiring the rights to brands like Sensodyne and Panadol in a $13 billion transaction that would later be reversed with the 2022 demerger of Haleon.
The FDA approves Shingrix, the recombinant zoster vaccine that utilizes the proprietary AS01 adjuvant platform to achieve a 97.2 percent efficacy rate, capturing 82 percent of the global shingles market and generating $4.2 billion in annual revenue.
GSK completes the demerger of its consumer healthcare division into the independent entity Haleon plc, a transaction valued at approximately $39 billion that eliminated the conglomerate discount and redirected capital toward high-margin specialty medicines.
The FDA approves Arexvy, the first RSV vaccine for adults over 60, which generated $1.9 billion in sales before suffering a catastrophic 74 percent year-over-year sales decline in Q3 2024 following US CDC ACIP guidance changes.
Luke Miels assumes the role of CEO on January 1, 2026, following the departure of Emma Walmsley, marking a decisive shift toward a ruthless, product-centric strategy that prioritizes late-stage clinical assets in oncology and immunology.
GSK anticipates the launch of the long-acting respiratory biologic Exdensur, a bispecific antibody that targets both IL-4 and IL-13, positioned to capture 22 percent of the $28 billion COPD market by 2030.
GSK acquired Sierra Oncology to secure rights to a novel myeloid malignancy drug platform, specifically the antibody-drug conjugate GSK-572, which targets the BCMA antigen in multiple myeloma and is currently in Phase 3 clinical trials.
GSK acquired IDRx, a developer of novel tyrosine kinase inhibitors that overcome resistance mutations in non-small cell lung cancer, to complement the ADC pipeline and provide a comprehensive oncology portfolio that can compete with the offerings of Novartis and Roche.
GSK acquired Pulmocide to secure rights to a proprietary lipid nanoparticle delivery system for inhaled gene therapies, a critical technology for the development of the cystic fibrosis treatment PM-101, which is currently in Phase 2 clinical trials.
In 2000 Glaxo Wellcome and SmithKline Beecham combined in a roughly $76 billion transaction that valued SmithKline Beecham at about a 60 percent premium to its pre-merger share price. The deal created GlaxoSmithKline with around $24 billion in annual revenue and roughly 100,000 employees, establishing a dominant position in the antidepressant, anti-ulcer, and respiratory therapeutic areas.
In 2022 the company rebranded from GlaxoSmithKline to GSK plc, adopting a simplified corporate identity to mark its transformation into a focused biopharma business. The rebrand coincided with the July 2022 demerger of the consumer healthcare division into Haleon plc, a spin-off valued at approximately $39 billion.
Integrating the British research-led Glaxo Wellcome culture with SmithKline Beecham's American commercial culture triggered the departure of about 15,000 employees within the first two years and a $4.2 billion write-down of redundant R&D assets. The combined company's shares fell roughly 45 percent between 2000 and 2003 as clinical failures mounted before management stabilized the pipeline.
GSK traces its earliest roots to 1715, when apothecary Silvanus Bevan opened the Plough Court pharmacy in London, giving the modern company more than three centuries of continuous operating heritage. That lineage runs through the Allen & Hanburys, Glaxo, Wellcome, Beecham, and Smith Kline & French businesses before the 2000 merger unified them.
An initial merger attempt collapsed in 1998 over disputes about the valuation of each company's R&D pipeline and where the combined headquarters would sit. The two sides revived talks and closed the roughly $76 billion deal in 2000, driven by the need for scale against managed-care pricing pressure and the looming patent expiry of the antidepressant Paxil.